Testing alternative schedules of adjuvant immune checkpoint blockers - The need for well-designed clinical trials. (2023)
Attributed to:
Evaluating new healthcare technologies in cancer
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.ejca.2022.10.024
PubMed Identifier: 36427393
Publication URI: http://europepmc.org/abstract/MED/36427393
Type: Journal Article/Review
Volume: 178
Parent Publication: European journal of cancer (Oxford, England : 1990)
ISSN: 0959-8049